Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Fluticasone furoate /vilanterol (Breo Ellipta — GlaxoSmithKline) indication: chronic obstructive pulmonary disease. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). CDEC Final Recommendation; SR0358. 2014 Authors' conclusions The Canadian Drug Expert Committee (CDEC) recommends that fluticasone furoate/vilanterol (FF/V) be listed for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations, if clinical criteria are met. Indexing Status Subject indexing assigned by NLM MeSH Adrenergic beta-2 Receptor Agonists /adverse effects /pharmacology /therapeutic use; Androstadienes /adverse effects /pharmacology /therapeutic use; Benzyl Alcohols /adverse effects /pharmacology /therapeutic use; Bronchodilator Agents /therapeutic use; Chlorobenzenes /adverse effects /pharmacology /therapeutic use; Drug Combinations; Forced Expiratory Volume /drug effects; Glucocorticoids /adverse effects /pharmacology /therapeutic uses; Pulmonary Disease, Chronic Obstructive /drug therapy /physiopathology Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32015000174 Date abstract record published 06/03/2015 |